Rakovina Therapeutics Inc. provides updates on their cancer therapy development, targeting PTEN-deficient tumors with brain-penetrant ATR/mTOR inhibitors. The company’s approach fills gaps left by recent clinical setbacks in the field and has garnered interest from major pharmaceutical partners for their kt-3000 series of novel antibody-drug conjugate payloads. Prof. Mads Daugaard presented Rakovina’s AI-driven strategy at the 9th Annual DNA Damage Response Inhibitors Summit in Boston, emphasizing the need for brain-penetrant ATR inhibitors and the company’s dual-targeting approach. Rakovina aims to advance their innovative treatments through partnerships and proof-of-concept studies.

Read more at GlobeNewswire: Rakovina Therapeutics Reports Strong Industry Validation